FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Commercial · sales Growing orders while handling process development and analysis for about 130 early-stage biotechs.

  • Cumulative orders of KRW 50 billion, 760 projects and about 130 customers. Source

Roles often seen at this stageManufacturing & MSAT · Quality QA & QC · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Protium Science

A biologics contract development and manufacturing company handling process development, analysis and small-scale production of early drug candidates; a subsidiary of Tiumbio.

CDAMO services

Service

Contract development and manufacturing plus analysis, from checking a candidate's manufacturability to data for clinical entry.

Completion reported

Reached cumulative orders of KRW 50 billion across 760 projects five years after founding.

Official role guide

Protium Science careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 한국형 CDAMO 꿈꾸는 프로티움사이언스 ↗한국경제 · Published 2026-06-29 · Sources checked 2026-11-15 · Original unavailable
  2. 생태계 동반자 '프로티움' 500억 수주 "남다른 이유" ↗바이오스펙테이터 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable